Zobrazeno 1 - 10
of 131
pro vyhledávání: '"non-squamous NSCLC"'
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13123-13134 (2023)
Abstract Purpose The relationship between mutant KRAS and the risk of disease progression and death in advanced non‐squamous non‐small cell lung cancer (NSCLC) is still controversial among current studies, and the effects of distinct KRAS mutatio
Externí odkaz:
https://doaj.org/article/d71fba77233848f28d7d1af41d0e7980
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground This study aimed to compare the efficacy and safety of different treatment modalities for previously untreated advanced EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC).Methods This retrospective study included 196 adva
Externí odkaz:
https://doaj.org/article/c8e4c4a6444c472a993f789090db0ad9
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-11 (2022)
Abstract Non-small cell lung cancer (NSCLC) is one of the most malignant tumors. The study was carried out to investigate the prognostic value of Beclin 1, EGFR and ALK for this cancer. Patients diagnosed with non-squamous NSCLC and admitted to our h
Externí odkaz:
https://doaj.org/article/0a599fa1a2bd4a9090cbd322dcc7e977
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Butuo Li, Linlin Yang, Chao Jiang, Yueyuan Yao, Haoqian Li, Shuping Cheng, Bing Zou, Bingjie Fan, Linlin Wang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe addition of bevacizumab was found to be associated with prolonged survival whether in combination with chemotherapy, tyrosine kinase inhibitors or immune checkpoint inhibitors in the treatment landscape of advanced non-small cell lung c
Externí odkaz:
https://doaj.org/article/1a92e4cb4b54489ab980c2f42adc5125
Autor:
Peter W. Szlosarek, Akhila G. Wimalasingham, Melissa M. Phillips, Peter E. Hall, Pui Ying Chan, John Conibear, Louise Lim, Sukaina Rashid, Jeremy Steele, Paula Wells, Chiung‐Fang Shiu, Chih‐Ling Kuo, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Stephen Ellis, Marianne Grantham, Michael Sheaff
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6642-6652 (2021)
Abstract Introduction We evaluated the arginine‐depleting enzyme pegargiminase (ADI‐PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1‐deficient non‐squamous non‐small cell lung cancer (NSCLC) via a phase 1 dose‐exp
Externí odkaz:
https://doaj.org/article/fabac2ca189a4727aedc6bdbadb5864e
Autor:
Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Baohui Han
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 816-824 (2021)
Objective: This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Eligible patients were ran
Externí odkaz:
https://doaj.org/article/89f482a744bd43afbb9a85d6f45c28a5
Publikováno v:
Thoracic Cancer, Vol 12, Iss 13, Pp 1959-1972 (2021)
Abstract Background Circular RNAs (circRNAs) are covalently closed RNAs and are implicated in the development of non‐small cell lung cancer (NSCLC). Here, we identified the precise actions of circRNA LIM domain binding 2 (circLDB2, hsa_circ_0069244
Externí odkaz:
https://doaj.org/article/d6d98cc13f8f46e9b0264053b0ff0f84
Autor:
Rui Wan, Xiaorong Dong, Qun Chen, Yan Yu, Shujun Yang, Xiaochun Zhang, Guojun Zhang, Yueyin Pan, Sanyuan Sun, Chengzhi Zhou, Wei Hong, Hui Zhao, Lei Yang, Linian Huang, Rong Wu, Aimin Zang, Rui Ma, Lin Wu, Dongqing Lv, Xiuhua Fu, Jianguo Han, Wenxin Li, Jianchun Duan, Kai Wang, Ou Jiang, Yinglan Chen, Zhongliang Guo, Hongjun Gao, Juyi Wen, Shubin Wang, Enfeng Zhao, Gaofeng Li, Lu Yue, Li Liang, Aiping Zeng, Xiaoshan Wang, Yuxi Zhu, Hongming Pan, Zhaoxia Dai, Weineng Feng, Guofang Zhao, Chuan Lin, Chong Li, Na Li, Yangyi Bao, Yinyin Li, Yanjun Su, Min Zhao, Haohui Fang, Yulong Zhu, Yu Zhang, Lieming Ding, Yang Wang, Xiaobin Yuan, Jie Wang
Publikováno v:
EClinicalMedicine, Vol 42, Iss , Pp 101187- (2021)
Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-bl
Externí odkaz:
https://doaj.org/article/fdbc7c412b564497a8805b161236dd76
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.